Good year, bad year? Two biotech CEOs hit pay dirt in 2018 as compensation packages swell
By any accounting measure, John Oyler had a big year last year, steering BeiGene to a monster $903 million Hong Kong IPO, then watching the stock languish as the China-based biotech put its PD-1 on a track to regulators. But whatever shortcomings may have been in the mix at BeiGene, they didn’t prevent the CEO from scoring one of the richest compensation packages in biopharma.
In a recent filing with the SEC BeiGene $BGNE revealed that the company founder made off with a compensation deal worth $27.9 million, a big step up from the $10.3 million he snagged in 2017 and the relatively modest $4.6 million he got for 2016 — the year BeiGene’s first IPO hit Nasdaq.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.